Abstract
The pathological DNA-specific B cells in Systemic lupus erythematosus are a logical target for a selected therapeutic intervention. It has been recently shown that complement receptor type 1 on human B and T-lymphocytes has suppressive activity. The cocrosslinking of this receptor with the B-cell receptor (BCR) inhibits B cell activation and proliferation and it could be an attractive new target for negative signal delivery. Experimental therapy in humans is limited by many restrictions. Severe combined immunodeficiency (SCID) mice, which lack both T and B lymphocytes and accept xenogenic cells have been used for human cell transfer for evaluating the pathogenesis of human SLE. We hypothesize that it may be possible to re-establish tolerance to native DNA in humanized SCID mice with cells transferred from SLE patients by administering to them a chimeric molecule, containing a monoclonal antibody against human inhibitory complement receptor type 1 coupled to a decapeptide DWEYSVWLSN that mimics DNA antigenically. These protein-engineered molecules are able to cocrosslink selectively the antigen receptors of B-cells possessing anti-native DNA specificity with the inhibitory surface receptors, thus delivering a strong suppressive signal.
Keywords: SCID models of SLE, Inhibitory B cell receptors, Chimeric molecules, erythematosus, xenogenic, chimeric, decapeptide, DWEYSVWLSN, proteinuria, quinacrine, chloroquine, Epratuzumab, Lymphostat-B, glomerulonephritis, Rituximab, immunoglobulin, lymphadenopathy, splenomegaly
Current Pharmaceutical Design
Title: Humanized SCID Mice Models of SLE
Volume: 17 Issue: 13
Author(s): Nikola Kerekov, Nikolina Mihaylova, Jozsef Prechl and Andrey Tchorbanov
Affiliation:
Keywords: SCID models of SLE, Inhibitory B cell receptors, Chimeric molecules, erythematosus, xenogenic, chimeric, decapeptide, DWEYSVWLSN, proteinuria, quinacrine, chloroquine, Epratuzumab, Lymphostat-B, glomerulonephritis, Rituximab, immunoglobulin, lymphadenopathy, splenomegaly
Abstract: The pathological DNA-specific B cells in Systemic lupus erythematosus are a logical target for a selected therapeutic intervention. It has been recently shown that complement receptor type 1 on human B and T-lymphocytes has suppressive activity. The cocrosslinking of this receptor with the B-cell receptor (BCR) inhibits B cell activation and proliferation and it could be an attractive new target for negative signal delivery. Experimental therapy in humans is limited by many restrictions. Severe combined immunodeficiency (SCID) mice, which lack both T and B lymphocytes and accept xenogenic cells have been used for human cell transfer for evaluating the pathogenesis of human SLE. We hypothesize that it may be possible to re-establish tolerance to native DNA in humanized SCID mice with cells transferred from SLE patients by administering to them a chimeric molecule, containing a monoclonal antibody against human inhibitory complement receptor type 1 coupled to a decapeptide DWEYSVWLSN that mimics DNA antigenically. These protein-engineered molecules are able to cocrosslink selectively the antigen receptors of B-cells possessing anti-native DNA specificity with the inhibitory surface receptors, thus delivering a strong suppressive signal.
Export Options
About this article
Cite this article as:
Kerekov Nikola, Mihaylova Nikolina, Prechl Jozsef and Tchorbanov Andrey, Humanized SCID Mice Models of SLE, Current Pharmaceutical Design 2011; 17 (13) . https://dx.doi.org/10.2174/138161211795703780
DOI https://dx.doi.org/10.2174/138161211795703780 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Innate Immunity and the Role of Epithelial Barrier During Aspergillus fumigatus Infection
Current Immunology Reviews (Discontinued) Crosstalk Between Histamine and T Cells in Allergic Diseases
Current Immunology Reviews (Discontinued) Immunotherapy of Pancreatic Carcinoma
Reviews on Recent Clinical Trials Carbon Nanotubes – Curse or Blessing
Current Medicinal Chemistry New Potential Pharmaceutical Applications of Hypericum Species
Mini-Reviews in Medicinal Chemistry Recent Advancements in Diagnosis and Therapy of Liver Cirrhosis
Current Drug Targets COVID-19 Induces Cytokine Storm and Dysfunctional Hemostasis
Current Drug Targets Fenofibrate: A New Treatment for Diabetic Retinopathy. Molecular Mechanisms and Future Perspectives
Current Medicinal Chemistry ACKNOWLEDGEMENTS TO REVIEWERS
Recent Patents on Inflammation & Allergy Drug Discovery 1,3-Dipolar Cycloadditions in the Synthesis of Carbohydrate Mimics. Part 1: Nitrile Oxides and Nitronates
Current Organic Chemistry Therapeutic Monoclonal Antibodies: Strategies and Challenges for Biosimilars Development
Current Medicinal Chemistry The Association of Fractalkine Receptor (T280M) Polymorphism in the Pathogenesis of Acute Coronary Syndrome in the Egyptian Population
Current Pharmaceutical Biotechnology Apobec3G-Based Strategies to Defeat HIV Infection
Current HIV Research Impact of the Renin-Angiotensin-Aldosterone-System on Cardiovascular and Renal Complications in Diabetes Mellitus
Current Vascular Pharmacology Coronavirus Disease 2019 and Hypertension: How Anti-hypertensive Drugs Affect COVID-19 Medications and <i>Vice Versa</i>
Current Drug Safety Chlorella vulgaris Induces Apoptosis of Human Non-Small Cell Lung Carcinoma (NSCLC) Cells
Medicinal Chemistry BHUx: A Patented Polyherbal Formulation to Prevent Hyperlipidemia and Atherosclerosis
Recent Patents on Inflammation & Allergy Drug Discovery Inhibition of microRNA-155 Alleviates Cognitive Impairment in Alzheimer’s Disease and Involvement of Neuroinflammation
Current Alzheimer Research Endogenous BMP-4/ROS/COX-2 Mediated IPC and Resveratrol Alleviated Brain Damage
Current Pharmaceutical Design Herb-Drug Interactions: An Evidence Based Approach
Current Medicinal Chemistry